Skip to main content Skip to main navigation menu Skip to site footer
GRHTA_logo
  • About
    • About the Journal
    • Editorial board
    • The Publisher
    • Publication ethics
    • Abstracting and indexing
    • Privacy Statement
    • Contact
  • Policies
    • Open access policy
    • Editorial policies
    • Self archiving and sharing policy
    • Commercial policies
    • Privacy policy
  • Guidelines
    • Guidelines for Authors
    • Guidelines for Reviewers
    • Guidelines for Artwork
    • Publication fees
    • Content type
  • Archives
  • Latest articles
Search
  • Register
  • Login
  • Submit now
  1. Home /
  2. Archives /
  3. Vol. 2 No. 1 (2015): January-April 2015 /
  4. Correspondence

New oncological therapies and the "right" price

Authors

  • Enrico Bosone Direttore Corporate Affairs and Market Access, Celgene srl, Milano - Italy

DOI:

https://doi.org/10.33393/grhta.2015.325

Downloads

  • PDF (Italian)

How to Cite

Bosone, E. (2015). New oncological therapies and the "right" price. Global and Regional Health Technology Assessment, 2(1), 59–60. https://doi.org/10.33393/grhta.2015.325
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 2 No. 1 (2015): January-April 2015

Section

Correspondence

License

Copyright (c) 2015 The authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

Metrics

Crossref
Scopus
Google Scholar
Europe PMC

Statistics

  • Abstract views - 591 times
  • PDF (Italian) downloads - 558 times

Sign up

Browse

  • Sections
    • Health Technology Assessment
    • Health Policies

banners150

0.8
2023CiteScore
 
 
28th percentile
Powered by  Scopus

Completed peer reviews since:
November 4, 2020

 

 

Most popular articles in the last 30 days
  • Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
    234
  • Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices
    217
  • Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals
    203
  • Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)
    198
  • Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)
    193

Global & Regional Health Technology Assessment | eISSN 2283-5733

AboutScience Srl  | Piazza Duca d’Aosta, 12 | 20124 Milano (MI) - Italy
Tel +39 02 2772 9949 | www.aboutscience.eu | VAT IT10418650965 | Privacy policy | Cookie Policy

 Linkedin    Platform and workflow OJS/PKP | Hosting Archimede Informatica | Customizations e-Danex Digital Solutions

More information about the publishing system, Platform and Workflow by OJS/PKP.